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Peptides show great pharmaceutical potential as active drugs in different therapeutic areas like allergy, anti-infection, oncology, obesity, etc and as functional excipients in drug 
delivery systems to overcome tissue and cellular membrane barriers. The development of a peptide toward a pharmaceutical compound poses however unique challenges: the 
rational development of its quality specifications is one of the major issues in this process. We present here the current regulatory quality status for peptide drugs. Differences 
and similarities in guidelines and pharmacopoeial differences will be highlighted, leading to a proposal of a consistent basic monograph.
RESULTS
CONCLUSIONS
Different origins of pharmacopoeial peptides:
•Biological: cells (n = 5/25) and tissues (n = 4/25)
•Biotechnological (rDNA) (n = 5/25)
•Synthetic (n = 11/25)
Non-pharmacopoeial peptides (e.g. ganirelix, cetrorelix, depreotide)
ICH guidelines:
•Explicit mentioned: Q5C, Q5E, Q6A/B
•Explicit excluded: Q3A/B
•Open/all types: Q1, Q2, Q3C, Q5A, Q7, Q8, Q9, Q10
Ph. Eur. Monograph 2034 + related 5.10 (concept of ODIs in decision tree):
•Currently: API peptides explicitly excluded from related substances section
•Proposal: RT = 0.1%, IT = 0.5%, QT = 1.0%
A peptide-drug monograph should basically consist of appearance, solubility information (important for analytical/product development, e.g. adsorption), identification by HPLC- 
UV, related impurities by HPLC-UV, residual solvents (water, acetic acid, others), sulphated ash, microbial purity and assay by HPLC-UV. Related substances are expected to 
adhere to thresholds of reporting (0.1%), identification (0.5%) and qualification (1.0%). Individual impurities should primarily focus on deamidation, epimers, oxidation and 
HMWP. Total related impurities are generally below 5%. Depending on the peptide-origin (synthetic, rDNA, cell- or tissue-based), this basic specification-set is to be 
supplemented with appropriate unrelated impurities (e.g. DNA, proteins, metals, specific organic solvents).
# Name # AA
Pharmacopoeia (1)
Origin
Ph. Eur. acceptance criteria on related substances (%) USP acceptance criteria on related substances (%)
Ph. Eur. USP Specified Unspecified Total DL Specified Unspecified Total DL
1 Bacitracin 11 0465 1483 B. licheniformis or B.subtilis 6.0 20.0 (4) - 0.5 No (2)
2 Buserelin 9 1077 - Synthetic 3 (6) 3 5 0.1 NA (3)
3 Calcitonin (salmon) 32 0471 1595 Synthetic or rDNA 3.0 / 0.6 / 0.2 - 5.0 0.1 - 3.0 5.0 0.1
4 Colistin sulphate 10 0320 1847 B.polymyxa var. colistinus - 4.0 23.0 × (5)
5 Desmopressin 9 0712 1897 Synthetic - 0.5 1.5 0.05 - 0.5 1.5 -
6 Felypressin 9 1634 - Synthetic 0.5 0.1 3.0 0.05 NA (3)
7 Glucagon 29 1635 2277
rDNA (Ph.Eur., human)
Pork/ox pancreas (USP)
0.5 (6) - 2.5 - - 2.5 10.0 -
8 Gonadorelin acetate 10 0827 2291 Synthetic - 2 5 0.05 - 1 2 0.05
9 Goserelin 9 1636 - Synthetic 1.0 / 0.5 0.5 2.5 0.05 NA (3)
10 Gramicidin 15 0907 2300 Brevibacillus brevis Dubos 2.0 / 1.0 2.0 / 1.0 - × (5) No (2)
11a Insulin aspart 51 2084 - rDNA 1.0 / 2.0 & 0.5 (6) 1.5 (4) - - NA (3)
11b Insulin, bovine 51 1637 2403 Ox (bovine) pancreas 3.0 & 1.0 (6) 3.0 (4) - - 1.0 / 10.0 & 1.0 (6) 5.0 (4) - -
11c Insulin, human 51 0838 2405 Pork pancreas or rDNA 2.0 / 1.0 & 1.0 (6) 2.0 (4) - - 2.0 & 1.0 (6) 2.0 (4) - -
11d Insulin lispro 51 2085 2408 rDNA 1.0 & 0.25 (6) 0.5 & 2.0 (4) - - 1.0 & 0.25 (6) 0.50 & 2.00 (4) - -
11e Insulin, porcine 51 1638 2403 Pork pancreas 2.0 & 1.0 (6) 2.0 (4) - - 1.0 / 10.0 & 1.0 (6) 5.0 (4) - -
12 Leuprorelin (leuprolide) 9 1442 2510 Synthetic 1 / 0.5 0.5 2.5 0.1 1.0 / 0.5 0.5 2.5 -
13 Oxytocin 9 0780 2897 Synthetic - 1.5 5 0.1 × (7) - 5 -
14 Polymyxin B sulphate 10 0203 3023 Paenibacillus polymyxa - 3.0 17.0 × (5) No (2)
15 Protirelin 3 1144 - Synthetic 2 2 3 0.05 NA (3)
16 Somatostatin 14 0949 - Synthetic - 1 2 0.03 NA (3)
17 Tetracosactide 24 0644 - Synthetic 4 5.0 / 2.5 - - NA (3)
18 Tyrothricin 10 & 15 1662 3487 Brevibacillus brevis Dubos No (2) No (2)
19 Vasopressin 9 - 3502 Synthetic or  pork/ox pituitary NA (3) × (7) - 5 -
-: absent; DL: disregard limit; (1)  Ph. Eur.: 01/2008 monograph number; USP 31: page; (2)  No: no related substances test described in monograph; (3)  Not applicable: peptide is not described in pharmacopoeia; (4)  Acceptance limit on sum of 
unspecified impurities; (5)  No quantitatively defined disregard limit, but “diluted reference standard” operationally defined; (6)  Acceptance limit on sum of two or more specified impurities; (7) Acceptance limit not defined in %, but as USP units.
Table I: Pharmacopoeial peptides & related impurities acceptance criteria (incl. high molecular weight peptides)
Quality attribute Method
No. of times included
Quality attribute Method
No. of times included
Quality attribute Method
No. of times included
Ph. Eur. only USP only Both Ph. Eur. only USP only Both Ph. Eur. only USP only Both
Description Tests (continued) Tests (continued)
Appearance Visual 10 0 8 Colour of solution Visual 3 0 0 Pyrogens Biological 0 0 1
Solubility H2O Visual 9 0 8 Optical rotation Polarimetry 8 0 3 Sterility Microbiological 0 3 1
Solubility solvents Visual 8 0 7 Specific absorbance UV spectrophotometry 4 0 0 PLI Immunochemical 1 0 0
Identification Absorbance ratio UV spectrophotometry 1 0 0 Zinc AAS 0 1 1
HPLC 8 0 9 Amino acid profile AA analysis 1 2 1 Heavy metals Chemical 0 3 0
AA analysis 8 0 0 Related substances HPLC Bioidentitty Biological 0 2 0
TLC 6 0 1 Specified impurities 9 2 2 Residual solvents GC 0 1 0
HPLC peptide mapping 2 0 1 Unspecified impurities 9 1 4 Microbial purity Microbiological 0 4 0
2D planar peptide mapping 1 0 0 Sum of impurities 8 1 6 Nitrogen content Kjeldahl 0 1 0
MS 0 3 0 Related substances TLC Crystalinity Optical microscopy 0 1 0
Colour reaction 0 1 2 Unspecified impurities 1 0 0 Melting temperature Melting in capillary 0 1 0
UV spectrophotometry 0 0 1 Peptide content HPLC 1 0 0 Phenylalanine UV spectrophotometry 0 1 0
IR 1 0 1 Acetic acid HPLC or GC 7 0 4 Fluoride Ion selective electrode 0 1 0
Zinc (chemical) 0 0 2 Water Karl Fischer 7 0 5 Trifluoroacetic acid HPLC 0 1 0
Sulphate (chemical) 1 0 0 Bacterial endotoxins LAL 9 0 4 Particulate matter Visual 0 1 0
1H NMR 2 0 0 Acetic acid + water Calculation 1 0 0 Assay
Biological test 1 1 0 Composition HPLC 3 0 0 HPLC 9 1 5
Tests Loss on drying Drying 0 0 6 Microbiological 0 2 3
pH of solution Potentiometric 1 1 3 Sulphated ash Ignition 3 1 4 Amino acid analysis 0 1 0
Clarity of solution Visual 4 1 0 Sulphate Titration 2 0 0 Biological 1 1 0
Table II: Pharmacopoeial peptide test method & occurrence in monographs
USP greater variety in tests than more consistent Ph. Eur.: room for improvement
